(Circulation. 2001;103:2876.)
© 2001 American Heart Association, Inc.
Editorial |
From the Department of Pathophysiology, Center of Internal Medicine, University School of Medicine, Essen, Germany.
Correspondence to Prof. Dr. Med. Dr. h. c. Gerd Heusch, Direktor der Abteilung für Pathophysiologie, Zentrum für Innere Medizin, Universitätsklinikum Essen, Hufelandstr 55, 45122 Essen, Germany. E-mail gerd.heusch@uni-essen.de
Key Words: Editorials heart diseases pharmacology ischemia reperfusion
Short episodes of ischemia and reperfusion protect the myocardium from the damage induced by episodes of sustained ischemia. Such ischemic preconditioning is apparent within minutes and lasts for 2 to 3 hours; a second phase of delayed preconditioning reappears 12 to 24 hours later and lasts for 3 to 4 days. Ischemic preconditioning, in its early and delayed form, is currently the prevailing paradigm for experimental studies aiming to reduce infarct size and other deleterious consequences of ischemia/reperfusion.1 A more detailed analysis of the underlying signal transduction is expected to provide better insight into the basic pathophysiology of myocardial ischemia/reperfusion injury and to help develop more potent and specific pharmacological treatments.
The existence and significance of ischemic
preconditioning in humans are less
clear,2 largely because the
most rigorous end point, infarct size, is not easily available in
controlled, prospective studies in humans, for obvious ethical reasons.
Prospective clinical studies with short episodes of fully reversible
myocardial ischemia, such as that induced by
percutaneous transluminal coronary angioplasty
(PTCA)3 4 5 6
or by brief surgical ischemic cardiac
arrest,7 8 are
available. Certain parts of the experimentally established signal
transduction of ischemic preconditioning have been verified
using PTCA; these include preconditioning by
adenosine9 10
or bradykinin11 and the
prevention of ischemic preconditioning by the ATP-sensitive
calcium channel (KATP) blocker
glibenclamide4 or the opioid
antagonist
naloxone.12 Surrogate end
points in such studies include ST-segment shifts in the surface or
intracoronary ECG, metabolic markers such as
lactate and ATP, or the release of creatine kinase and troponin.
Although
This article has been cited by other articles:
![]() |
G. Ambrosio, M. Del Pinto, I. Tritto, G. Agnelli, M. Bentivoglio, C. Zuchi, F. A. Anderson, J. M. Gore, J. Lopez-Sendon, A. Wyman, et al. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52 693 patients in the Global Registry of Acute Coronary Events Eur. Heart J., November 10, 2009; (2009) ehp457v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Heusch, P. Kleinbongard, D. Bose, B. Levkau, M. Haude, R. Schulz, and R. Erbel Coronary Microembolization: From Bedside to Bench and Back to Bedside Circulation, November 3, 2009; 120(18): 1822 - 1836. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Heusch A BEAUTIFUL lesson--ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more? Eur. Heart J., October 1, 2009; 30(19): 2300 - 2301. [Full Text] [PDF] |
||||
![]() |
G. Heusch and R. Schulz Neglect of the coronary circulation: some critical remarks on problems in the translation of cardioprotection Cardiovasc Res, October 1, 2009; 84(1): 11 - 14. [Full Text] [PDF] |
||||
![]() |
K. Boengler, R. Schulz, and G. Heusch Loss of cardioprotection with ageing Cardiovasc Res, July 15, 2009; 83(2): 247 - 261. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Peart and J. P. Headrick Clinical cardioprotection and the value of conditioning responses Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1705 - H1720. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Heusch, K. Boengler, and R. Schulz Cardioprotection: Nitric Oxide, Protein Kinases, and Mitochondria Circulation, November 4, 2008; 118(19): 1915 - 1919. [Full Text] [PDF] |
||||
![]() |
G. Niccoli, L. Altamura, A. Fabretti, G. A. Lanza, L. M. Biasucci, A. G. Rebuzzi, A. M. Leone, I. Porto, F. Burzotta, C. Trani, et al. Ethanol Abolishes Ischemic Preconditioning in Humans J. Am. Coll. Cardiol., January 22, 2008; 51(3): 271 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ferdinandy, R. Schulz, and G. F. Baxter Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning Pharmacol. Rev., December 1, 2007; 59(4): 418 - 458. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dragoni, T. Gori, M. Lisi, G. Di Stolfo, A. Pautz, H. Kleinert, and J. D. Parker Pentaerythrityl Tetranitrate and Nitroglycerin, but not Isosorbide Mononitrate, Prevent Endothelial Dysfunction Induced by Ischemia and Reperfusion Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 1955 - 1959. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Leesar, H. Jneid, X.-L. Tang, and R. Bolli Pretreatment with intracoronary enalaprilat protects human myocardium during percutaneous coronary angioplasty. J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1607 - 1610. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Boengler, R Schulz, and G Heusch Connexin 43 signalling and cardioprotection Heart, December 1, 2006; 92(12): 1724 - 1727. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Guo, A. B. Stein, W.-J. Wu, X. Zhu, W. Tan, Q. Li, and R. Bolli Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and {delta}1-opioid receptor agonists is mediated by iNOS Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2251 - H2257. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Boengler, G. Dodoni, A. Rodriguez-Sinovas, A. Cabestrero, M. Ruiz-Meana, P. Gres, I. Konietzka, C. Lopez-Iglesias, D. Garcia-Dorado, F. Di Lisa, et al. Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning Cardiovasc Res, August 1, 2005; 67(2): 234 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Wang, D. A. Liem, T. M. Vondriska, H. M. Honda, P. Korge, D. M. Pantaleon, X. Qiao, Y. Wang, J. N. Weiss, and P. Ping Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1290 - H1295. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Heusch Postconditioning: Old wine in a new bottle? J. Am. Coll. Cardiol., September 1, 2004; 44(5): 1111 - 1112. [Full Text] [PDF] |
||||
![]() |
A. Crisafulli, F. Melis, F. Tocco, U. M. Santoboni, C. Lai, G. Angioy, L. Lorrai, G. Pittau, A. Concu, and P. Pagliaro Exercise-induced and nitroglycerin-induced myocardial preconditioning improves hemodynamics in patients with angina Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H235 - H242. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-L. Tang, Y.-T. Xuan, Y. Zhu, G. Shirk, and R. Bolli Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1273 - H1280. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. YELLON and J. M. DOWNEY Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology Physiol Rev, October 1, 2003; 83(4): 1113 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Lambiase, R. J. Edwards, M. R. Cusack, C. A. Bucknall, S. R. Redwood, and M. S. Marber Exercise-induced ischemia initiates the second window of protection in humans independent of collateral recruitment J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1174 - 1182. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Shinmura, E. Kodani, Y. u-T. Xuan, B. Dawn, X.-L. Tang, and R. Bolli Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1183 - 1194. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Przyklenk and G. Heusch Late preconditioning against myocardial stunning: Does aspirin close the "second window" of endogenous cardioprotection? J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1195 - 1197. [Full Text] [PDF] |
||||
![]() |
A. Skyschally, R. Schulz, P. Gres, H.-G. Korth, and G. Heusch Attenuation of ischemic preconditioning in pigs by scavenging of free oxyradicals with ascorbic acid Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H698 - H703. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Gres, R. Schulz, J. Jansen, C. Umschlag, and G. Heusch Involvement of endogenous prostaglandins in ischemic preconditioning in pigs Cardiovasc Res, August 15, 2002; 55(3): 626 - 632. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |